Paul Thomas Acquires Shares of Axogen, Inc.

On June 24, 2026, Paul Thomas made a notable insider purchase of 5,579 shares of Axogen, Inc. (NasdaqCM: AXGN). This transaction was not part of a pre-planned trading plan, suggesting a personal decision to invest in the company's future.

Insider Buying and Selling at Axogen, Inc.

Several insiders, including Paul Thomas, showed confidence in Axogen, Inc. by purchasing shares on June 24, 2026. Alongside Thomas, insiders Kathy Johnson, Joseph Tyndall, Amy McBride Wendell, William Burke, and John Johnson each bought 4,392 shares. These transactions were also not pre-planned, indicating a collective insider belief in the company's potential.

Other Institutional Activity in Axogen, Inc.

In recent institutional activity, First Light Asset Management, LLC reduced its holding by 1,230,558 shares, bringing its total to 4,002,768 shares worth approximately $132.6 million, a 23.5% decrease. Meanwhile, BlackRock, Inc. increased its stake by 151,414 shares, now holding 3,870,851 shares valued at about $128.2 million, reflecting a 4.1% increase. Morgan Stanley grew its holdings by 536,112 shares, resulting in a 20.7% increase to 3,122,982 shares worth $103.5 million. Vanguard Capital Management LLC opened a new position with 2,291,563 shares valued at $75.9 million. Arrowmark Colorado Holdings LLC and Wasatch Advisors LP also increased their positions by 29.9% and 101.1%, respectively.

Axogen, Inc. Stock Down 12.7%

Shares of Axogen, Inc. traded near $44.49 on Saturday. The company has a market capitalization of approximately $2.37 billion. Its forward P/E ratio stands at 61.1, indicating investor expectations for future earnings growth. The stock has a beta of 1.118, suggesting moderate volatility compared to the market. Over the past year, the shares have ranged between $10.20 and $46.00, with moving averages of $41.31 for 50 days and $30.96 for 200 days. Axogen maintains strong liquidity, with a current ratio of 7.10 and a quick ratio of 4.99, while its debt-to-equity ratio is low at 8.43.

Analysts Set New Price Targets

On April 29, 2026, Canaccord Genuity, Citizens, and Wells Fargo maintained their 'buy' ratings for Axogen, Inc., setting price targets of $50, $50, and $48, respectively. HC Wainwright & Co. also maintained a 'buy' rating with a $50 target. The consensus among nine analysts reflects an average target price of $50.78, indicating positive sentiment towards the stock.

About Axogen, Inc.

Axogen, Inc., based in Alachua, Florida, operates in the healthcare sector, specifically within the medical devices industry. The company focuses on developing and commercializing technologies for peripheral nerve regeneration and repair. Its product line includes Avance Nerve Graft and Axoguard Nerve Connector, among others, which are used in surgical repairs and protection of peripheral nerves. Led by CEO Lindsey Hartley, Axogen serves a variety of healthcare facilities and surgeons worldwide.

Bottom Line

Paul Thomas's recent purchase of Axogen, Inc. shares highlights insider confidence in the company's prospects. Axogen's stock performance and analyst ratings suggest a positive outlook, though investors should consider that insider transactions can reflect many factors. As always, it's important to note that 13F filings are backward-looking and may not represent current positions.